Endometrial stromal sarcoma extending to the pulmonary artery: A rare case report.

paythelady.612 shared this article with you from Inoreader Endometrial stromal sarcoma extending to the pulmonary artery: A rare case report. Μέσω pubmed: "world j clin cases"... Related Articles Endometrial stromal sarcoma extending to the pulmonary artery: A rare case report. World J Clin Cases. 2020 Nov 26;8(22):5625-5631 Authors: Fan JK, Tang GC, Yang H Abstract BACKGROUND: Endometrial stromal sarcoma (ESS) is a rare malignant mesenchymal tumor. Early in the disease, the findings on magnetic resonance imaging are similar to those of leiomyoma. When the lesion involves both vascular and cardiac tissue, it might be misdiagnosed as intravenous leiomyomatosis, which is not common in the clinic. CASE SUMMARY: We present the case of a 34-year-old female patient with tumor embolus, which extended from the right iliac vein and ovarian vein to the inferior vena cava (IVC), and then to the right atrium and right ventricle, and finally protruded into the pulmonary artery. The patient had undergone a hystero-myomectomy 7 years previously. Based on the findings of the imaging examinations, the diagnosis of intravenous leiomyomatosis was considered preoperatively. The patient then underwent complete resection of the endovascular and intracardiac tumor embolus. The postoperative pathology results confirmed metastatic ESS with endovascular and intracardiac involvement. The patient was discharged from hospital in good condition, and there was no sign of recurrence 5 mo after the operation. CONCLUSION: Extending from the iliac vein and ovarian vein to the IVC, this metastatic ESS invaded both vascular and cardiac tissues. For patients with ESS involving vascular and cardiac tissues, pathological examinations are essential for the differential diagnosis, such as intravenous leiomyomatosis. In addition, due to the high recurrence rate of ESS, long-term and close follow-up evaluation is necessary. PMID: 33344553 [PubMed] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.